Date
26-27 February 2027
Venue
Vienna | Austria
Scientific Committee
Univ. Prof. Dr. Christoph Zielinski | Vienna | Austria
Priv. Doz. Dr. Christiane Thallinger, MBA MSc | Vienna | Austria
Assoc. Prof. Priv.-Doz. Dr. Gerald Prager | Vienna | Austria
Dr Teresa Macarulla | Barcelona | Spain
Programme
See here the 2026 programme
CME Accreditation
The Central European Oncology Group, as in previous years, will seek accreditation from the European Accreditation Council for Continuing Medical Education (EACCME). This will allow participants of the academy to earn CME credits, enhancing the educational value of their experience.
| Time | Session / Presentation |
|---|---|
| 13:00-13:15 | Welcome Session Christoph Zielinski, Austria Gerald Prager, Austria Teresa Macarulla, Spain |
| 13:15-14:45 | Metastatic Pancreatic Cancer: Which Chemotherapy Combination and for Whom? |
| Chairs | Gerald Prager, Austria; Christoph Zielinski, Austria |
| 13:15-13:45 | Experimental and Developing Treatment Options Mariano Ponz-Sarvisé, Spain |
| 13:45-14:15 | First Line Treatment of Metastatic PC Teresa Macarulla, Spain |
| 14:15-14:45 | Second Line Treatment of Metastatic PC Gerald Prager, Austria |
| 14:45-15:15 | Coffee Break |
| 15:15-17:45 | Understanding Pancreatic Cancer (PC) |
| Chairs | Cindy Neuzillet, France; Teresa Macarulla, Spain |
| 15:15-15:45 | Genomic Architecture of PDAC Berthold Streubel, Austria |
| 15:45-16:15 | Supportive Care in PDAC Cindy Neuzillet, France |
| 16:15-16:45 | Updated Version of PDAC ESMO Guidelines Michel Ducreux, France |
| 16:45-17:15 | Radiologic Diagnostic Options in Early and Metastatic PC Helmut Ringl, Austria |
| 17:15-17:45 | PDAC Case Presentation Participant Presentation |
| 17:15-18:45 | Welcome Reception |
| Time | Session / Presentation |
|---|---|
| 09:00-10:30 | Neoadjuvant Therapy of PC |
| Chairs | Teresa Macarulla, Spain; Davide Melisi, Italy |
| 09:00-09:30 | Oligometastatic Disease in Pancreatic Cancer Oliver Strobel, Austria |
| 09:30-10:00 | Patient Selection for Neoadjuvant Chemotherapy & Selecting the Optimal Chemotherapy Combination Davide Melisi, Italy |
| 10:00-10:30 | Is There a Place for Radiotherapy? Mariano Ponz-Sarvisé, Spain |
| 10:30-11:00 | Case Presentation |
| 10:30-11:00 | Biliary Tract Cancer Case Presentation Participant Presentation |
| 11:00-11:30 | Coffee Break |
| 11:30-14:00 | Diagnostic and Therapeutic Aspects in Cholangiocellular Cancer (CCC) |
| Chairs | Angela Lamarca, Spain; Harpreet Wasan, United Kingdom |
| 11:30-12:00 | Upcoming Molecular Targets in CCA Gerald Prager, Austria |
| 12:00-12:30 | Surgical Treatment of CCC: When to Intervene and With Which Benefit Tarik Ghadban, Germany |
| 12:30-13:00 | Perioperative Treatment Options Davide Melisi, Italy |
| 13:00-13:30 | Systemic Treatment Strategies in Advanced CCA: What Is Next? TBC |
| 13:30-14:00 | Treatment of Advanced CCC: Molecular Targeted Therapy Versus Immune Checkpoint Inhibitors Harpreet Wasan, United Kingdom |
| 14:00-14:15 | Closing Words Christoph Zielinski, Austria Gerald Prager, Austria Teresa Macarulla, Spain |